Payment overview · 2025
General Payments
$3,266.45
152 reported records · 32 companies
Healthcare provider profile · identity verified
Gregor Paronian, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PASADENA, CA · NPI 1366627945
Verified facts
What the public records show
CMS Open Payments records show Gregor Paronian, M.D. received $3,266.45 in general payments during 2025 across 152 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Trulance, Ubrelvy, Vraylar, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 476 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 476 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 338 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $536.52 | 16.4% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $445.88 | 13.7% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $387.50 | 11.9% | 28 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $165.51 | 5.1% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $164.73 | 5.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $154.60 | 4.7% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $125.62 | 3.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $105.48 | 3.2% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $94.39 | 2.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.35 | 2.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $89.69 | 2.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $83.09 | 2.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.91 | 2.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $72.76 | 2.2% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $71.87 | 2.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $59.64 | 1.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.88 | 1.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.52 | 1.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.10 | 1.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.08 | 1.5% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $46.74 | 1.4% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $42.90 | 1.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $32.52 | 1.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.00 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.57 | 0.9% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $27.68 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.62 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.44 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.89 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.38 | 0.6% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.97 | 0.6% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $15.62 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,266.45 | 152 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $437.91 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $342.09 | 26 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $342.09 | 26 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $254.87 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $216.25 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $165.51 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $154.60 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $146.37 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.47 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $145.45 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.27 | 10 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $125.62 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $114.68 | 5 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $94.39 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $91.35 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.40 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $72.78 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $71.87 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.03 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.97 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.88 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $49.10 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $46.74 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $42.90 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $32.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.87 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 98 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 338 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 227 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 68 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 465 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 476 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 239 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 398 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 263 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 173 | exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
98 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
476 | 67 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
113 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
227 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
117 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
465 | 75 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
263 | 49 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
476 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
465 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
239 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
116 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
398 | 70 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
338 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 32 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
173 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2263 | 392 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1415 | 254 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1162 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 1084 | 195 |
| Metformin Hcl | Metformin Hcl | 994 | 152 |
| Gabapentin | Gabapentin | 975 | 155 |
| Escitalopram Oxalate | Escitalopram Oxalate | 814 | 118 |
| Furosemide | Furosemide | 801 | 149 |
| Ibuprofen | Ibuprofen | 769 | 137 |
| Azelastine Hcl | Azelastine Hcl | 734 | 150 |
| Omeprazole | Omeprazole | 699 | 123 |
| Trazodone Hcl | Trazodone Hcl | 689 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 683 | 130 |
| Losartan Potassium | Losartan Potassium | 670 | 104 |
| Vascepa | Icosapent Ethyl | 618 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 597 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 594 | 100 |
| Lisinopril | Lisinopril | 567 | 99 |
| Dexlansoprazole Dr | Dexlansoprazole | 565 | 78 |
| Carvedilol | Carvedilol | 556 | 86 |
| Diclofenac Sodium | Diclofenac Sodium | 545 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 534 | 98 |
| Meclizine Hcl | Meclizine Hcl | 496 | 85 |
| Lorazepam | Lorazepam | 491 | 84 |
| Ketoconazole | Ketoconazole | 477 | 66 |
| Linzess | Linaclotide | 476 | 67 |
| Jardiance | Empagliflozin | 465 | 75 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 454 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 421 | 57 |
| Tramadol Hcl | Tramadol Hcl | 411 | 88 |
| Donepezil Hcl | Donepezil Hcl | 399 | 65 |
| Ozempic | Semaglutide | 398 | 70 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 368 | 82 |
| Azithromycin | Azithromycin | 360 | 231 |
| Repatha Sureclick | Evolocumab | 341 | 45 |
| Eliquis | Apixaban | 338 | 62 |
| Terazosin Hcl | Terazosin Hcl | 338 | 57 |
| Naproxen | Naproxen | 314 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 313 | 51 |
| Famotidine | Famotidine | 312 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 309 | 53 |
| Celecoxib | Celecoxib | 303 | 50 |
| Simvastatin | Simvastatin | 300 | 53 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 296 | 68 |
| Atenolol | Atenolol | 285 | 42 |
| Icosapent Ethyl | Icosapent Ethyl | 285 | 66 |
| Ezetimibe | Ezetimibe | 274 | 45 |
| Alprazolam | Alprazolam | 273 | 47 |
| Propranolol Hcl | Propranolol Hcl | 270 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 268 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 264 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 263 | 49 |
| Ventolin Hfa | Albuterol Sulfate | 261 | 43 |
| Finasteride | Finasteride | 251 | 40 |
| Irbesartan | Irbesartan | 247 | 53 |
| Montelukast Sodium | Montelukast Sodium | 245 | 34 |
| Mounjaro | Tirzepatide | 239 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 237 | 45 |
| Clonidine Hcl | Clonidine Hcl | 227 | 39 |
| Farxiga | Dapagliflozin Propanediol | 227 | 31 |
| Glipizide | Glipizide | 227 | 33 |
| Metformin Hcl Er | Metformin Hcl | 222 | 44 |
| Procto-Med Hc | Hydrocortisone | 217 | 30 |
| Allopurinol | Allopurinol | 211 | 44 |
| Sertraline Hcl | Sertraline Hcl | 204 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 199 | 35 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 198 | 31 |
| Benazepril Hcl | Benazepril Hcl | 196 | 34 |
| Clonidine | Clonidine | 192 | 26 |
| Pregabalin | Pregabalin | 190 | 27 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 185 | 22 |
| Lidocaine | Lidocaine | 183 | 35 |
| Baclofen | Baclofen | 175 | 26 |
| Clobetasol Propionate | Clobetasol Propionate | 175 | 31 |
| Meloxicam | Meloxicam | 175 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 24 |
| Trintellix | Vortioxetine Hydrobromide | 173 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 172 | 138 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 32 |
| Alendronate Sodium | Alendronate Sodium | 162 | 28 |
| Valsartan | Valsartan | 162 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 161 | 42 |
| Mirtazapine | Mirtazapine | 160 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 33 |
| Januvia | Sitagliptin Phosphate | 156 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 148 | 21 |
| Potassium Chloride | Potassium Chloride | 143 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 138 | 16 |
| Chlorthalidone | Chlorthalidone | 137 | 23 |
| Ondansetron Odt | Ondansetron | 136 | 52 |
| Lansoprazole | Lansoprazole | 130 | 24 |
| Hydrocortisone | Hydrocortisone | 128 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 126 | 17 |
| Spironolactone | Spironolactone | 119 | 18 |
| Buspirone Hcl | Buspirone Hcl | 117 | 23 |
| Nexium | Esomeprazole Magnesium | 117 | 11 |
| Fenofibrate | Fenofibrate | 116 | 17 |
| Trulicity | Dulaglutide | 116 | 15 |
| Myrbetriq | Mirabegron | 113 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 112 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 110 | 23 |
| Methimazole | Methimazole | 108 | 19 |
| Nifedipine Er | Nifedipine | 108 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 108 | 24 |
| Methylprednisolone | Methylprednisolone | 106 | 91 |
| Colchicine | Colchicine | 105 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 104 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 21 |
| Cyclosporine | Cyclosporine | 100 | 21 |
| Synthroid | Levothyroxine Sodium | 100 | 18 |
| Creon | Lipase/Protease/Amylase | 98 | 11 |
| Clonazepam | Clonazepam | 97 | 12 |
| Tradjenta | Linagliptin | 97 | 11 |
| Glipizide Er | Glipizide | 96 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 31 |
| Entresto | Sacubitril/Valsartan | 94 | 15 |
| Glimepiride | Glimepiride | 94 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 92 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 90 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 90 | 17 |
| Latanoprost | Latanoprost | 87 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 86 | suppressed |
| Memantine Hcl | Memantine Hcl | 84 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 82 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 21 |
| Ciclopirox | Ciclopirox | 79 | 21 |
| Nitroglycerin | Nitroglycerin | 79 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 78 | 11 |
| Bupropion Xl | Bupropion Hcl | 75 | 14 |
| Loperamide | Loperamide Hcl | 75 | 21 |
| Fluocinonide | Fluocinonide | 74 | 17 |
| Praluent Pen | Alirocumab | 73 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 61 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 71 | 12 |
| Sucralfate | Sucralfate | 70 | 15 |
| Gemtesa | Vibegron | 68 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 12 |
| Methocarbamol | Methocarbamol | 64 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 63 | 14 |
| Memantine Hcl Er | Memantine Hcl | 62 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 61 | suppressed |
| Dutasteride | Dutasteride | 59 | suppressed |
| Lactulose | Lactulose | 57 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 54 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 54 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 53 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 53 | suppressed |
| Livalo | Pitavastatin Calcium | 52 | suppressed |
| Restasis | Cyclosporine | 52 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Temazepam | Temazepam | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 49 | 11 |
| Novolog Flexpen | Insulin Aspart | 49 | 13 |
| Prednisone | Prednisone | 49 | 38 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Rybelsus | Semaglutide | 48 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 47 | suppressed |
| Cephalexin | Cephalexin | 47 | 41 |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Ibu | Ibuprofen | 47 | 11 |
| Nystatin | Nystatin | 45 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 45 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Diazepam | Diazepam | 43 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 14 |
| Lovastatin | Lovastatin | 43 | suppressed |
| Telmisartan | Telmisartan | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 20 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 40 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 39 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 39 | suppressed |
| Vraylar | Cariprazine Hcl | 38 | suppressed |
| Cilostazol | Cilostazol | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Ztlido | Lidocaine | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 33 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 33 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Niacin Er | Niacin | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Anastrozole | Anastrozole | 31 | suppressed |
| Clotrimazole | Clotrimazole | 31 | suppressed |
| Scopolamine | Scopolamine | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 28 | suppressed |
| Prolia | Denosumab | 28 | 17 |
| Kerendia | Finerenone | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 27 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Dayvigo | Lemborexant | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 13 |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 25 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 25 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 11 |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 23 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Ubrelvy | Ubrogepant | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Trulance | Plecanatide | 20 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 19 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Dexilant | Dexlansoprazole | 18 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Quviviq | Daridorexant Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Benicar | Olmesartan Medoxomil | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 12 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humira | Adalimumab | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,266.45 · 152 records | AstraZeneca Pharmaceuticals LP | APRETUDE, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, JOURNAVX, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, RELISTOR, REPATHA, REXULTI, REZDIFFRA, Rybelsus, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, TRULANCE, UBRELVY, VERQUVO, VOWST, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE, ZTLido | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error